Showing results (1-10 of 121) with videos related to
Sort By:
Pageof 13
Oncology (Williston Park, N.Y.)|December 20, 2003
Identifying predictive and surrogate markers of erlotinib antitumor activity other than rashDenis SoulièresCurrent Opinion in Supportive and Palliative Care|August 6, 2013
Side-effects associated with targeted therapies in renal cell carcinomaDenis SoulièresCurrent Opinion in Supportive and Palliative Care|June 11, 2009
Advanced renal cell carcinoma: what to do after first line antiangiogenic therapy?Denis SoulièresThe Canadian Journal of Urology|April 15, 2009
Hypofractionated radiotherapy with concomitant sunitinib - is there a radiosensitizing effect?Daniel Taussky, Denis SoulièresExpert Opinion on Drug Safety|May 28, 2020
Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinomaAntoine Desilets, Denis SoulièresCancer Journal (Sudbury, Mass.)|September 27, 2022
PI3K Inhibition for Squamous Cell Head and Neck CarcinomaAntoine Desilets, Denis SoulièresExpert Opinion on Emerging Drugs|April 15, 2024
Emerging monoclonal antibody therapy for head and neck squamous cell carcinomaFrancis Proulx-Rocray, Denis SoulièresThe Canadian Journal of Urology|February 28, 2007
Isolated solitary bony metastasis of a nonseminomatous germ cell tumorAbdulhadi Aldejmah, Denis Soulières, Fred SaadAmerican Journal of Clinical Oncology|October 11, 2008
Antineoplastic properties of bacteriocins: revisiting potential active agentsGilbert Cornut, Claude Fortin, Denis SoulièresThe Journal of Pathology. Clinical Research|August 9, 2016
ReadMax-a novel reading and scoring approach for EGFR gene copy number to predict therapeutic benefit of erlotinib treatment in EGFR wild-type non-small-cell lung cancerJoachim Moecks, Denis Soulières, Barbara KlughammerPageof 13